OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Investigator: Frank Menniti

1 Projects | 1 Researchers | $5,014,485 Invested

2026

MindImmune Therapeutics, Inc.

Frank Menniti, PhD

MITI-101, a novel antibody therapeutic to treat Alzheimer's disease and related disorders

  • Funding Amount: $5,014,485
  • Organization Type:
  • Program: Clinical
  • Target: Inflammation
  • Status: Active